Weiyun Z. Ai, MD, PhD, discusses some of the most pivotal advances that have been made in the fields of T-cell lymphoma and Hodgkin lymphoma in recent years.
The FDA has granted a priority review designation to a supplemental new drug application for olaparib (Lynparza) for the treatment of patients with metastatic castration-resistant prostate cancer who have deleterious or suspected deleterious or somatic homologous recombination repair gene mutations, and who have also progressed on prior therapy with a new hormonal agent.
Neil Dunavin, MD, MS, highlights criteria to consider when approaching treatment selection for patients with myelofibrosis and discussed next steps for the field.
Charalambos (Babis) Andreadis, MD, MSCE, discusses immunotherapeutic advances in MCL and DLBCL based on data from the 2019 ASH Annual Meeting.
Thomas G. Martin, MD, discusses the current treatment approaches in multiple myeloma, as well as the agents that are generating excitement in relapsed/refractory patient populations.
Josep Tabernero, MD, PHD, MSc, is best known for applying translational research against gastrointestinal tumors, with particular focus on colorectal cancer.
Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.
The National Institute for Health and Care Excellence does not recommend larotrectinib for the treatment of advanced NTRK fusion–positive solid tumors in adults and children without satisfactory treatment options.
Although small molecule inhibitors of the Hedgehog signaling pathway have transformed the treatment paradigm for advanced basal cell carcinoma, the most common form of skin cancer, efforts to expand their use to other tumor types have proved elusive.
Anecdotes of gender inequality and sexual harassment abound among gynecologic oncologists, but until recently, there had been no study to measure the problem in this profession. Findings reported in June 2019 suggesting that high numbers of men and women in this field were subject to sexual harassment were no surprise to investigators. Instead, they have strengthened national gender discrimination and sexual harassment reform efforts in oncologic gynecology.